Isavuconazole is the last antifungal agent approved by the FDA and available for treatment of fungal infections. In the present study, the in vitro activity of isavuconazole against several yeasts was investigated. Two hundred forty-six isolates were included: 64 Candida albicans , 53 Candida parapsilosis sensu stricto, 48 Cryptococcus neoformans species complex, 27 C. glabrata sensu stricto, 17 C. lusitaniae , 17 C. tropicalis , 5 C . orthopsilosis , 4 C. krusei , 3 C. guilliermondii sensu stricto, 3 C. pelliculosa , 2 C . dubliniensis , 1 C . auris , 1 C . fermentati and 1 Trichosporon asahii . All isolates were recovered from clinical isolates from Chile, being 221 from hemoculture, 22 from cerebrospinal fluid, 1 pleural fluid, and 1 from tissue culture. The minimal inhibitory concentrations (MICs) and minimal fungicidal concentrations (MFCs) of isavuconazole were determined. Isavuconazole demonstrated good in vitro activity against all species tested. MIC90 values and MFC ranges of isavuconazole for Candida albicans were 0.03 mg/L and 0.03– > 16 mg/L respectively. Non– Candida albicans species isolates were inhibited by ≤ 1 mg/L, with MFC ranges from < 0.03– > 16 mg/L. Also, isavuconazole was active against the non- Candida yeasts, being inhibited with MIC values ≤ 0.06 mg/L. Isavuconazole has exhibited potent in vitro activity against clinical isolates of Candida spp., Cryptococcus neoformans species complex, and other clinical yeast in Chile. Despite the results obtained in the present work, additional clinical studies are necessary to verify the level of efficacy of this azole.

中文翻译：

---

艾沙康唑对智利临床分离酵母的体外活性

艾沙康唑是 FDA 批准的最后一种抗真菌剂，可用于治疗真菌感染。在本研究中，研究了艾沙康唑对几种酵母菌的体外活性。包括246个分离株：64个白色念珠菌，53个近平滑念珠菌，48个新型隐球菌种复合体，27个光滑念珠菌，17个念珠菌，17个热带念珠菌，5个。orthopsilosis , 4 C. krusei , 3 C. guilliermondii sensu stricto, 3 C. pelliculosa, 2 C. dubliniensis , 1 C. 耳，1 C。发酵和 1 Trichosporon asahii 。所有分离株均来自智利的临床分离株，其中 221 株来自血液培养，22 株来自脑脊液，1 株胸水和 1 株来自组织培养。确定艾沙康唑的最小抑菌浓度 (MIC) 和最小杀真菌浓度 (MFC)。艾沙康唑对所有测试物种均表现出良好的体外活性。艾沙康唑对白色念珠菌的 MIC90 值和 MFC 范围分别为 0.03 mg/L 和 0.03– > 16 mg/L。非白色念珠菌种分离物被抑制 ≤ 1 mg/L，MFC 范围为 < 0.03– > 16 mg/L。此外，艾沙康唑对非念珠菌酵母菌具有活性，其 MIC 值≤ 0.06 mg/L 时被抑制。Isavuconazole 对智利的念珠菌属、新型隐球菌种复合体和其他临床酵母菌的临床分离株表现出有效的体外活性。尽管在目前的工作中获得了结果，但仍有必要进行额外的临床研究来验证这种唑的功效水平。